Ignite Creation Date:
2025-12-24 @ 9:55 PM
Ignite Modification Date:
2025-12-25 @ 7:33 PM
Study NCT ID:
NCT01933932
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-19
First Post:
2013-08-29
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-09-25
Start Date Type:
ACTUAL
Primary Completion Date:
2016-06-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2013-08-29
First Submit QC Date:
None
Study First Post Date:
2013-09-02
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-02-27
Results First Submit QC Date:
None
Results First Post Date:
2017-08-29
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-12
Last Update Post Date:
2025-11-19
Last Update Post Date Type:
ESTIMATED